Cognition Therapeutics (NASDAQ: CGTX) — Perfil da empresa, notícias e dados financeiros
Cognition Therapeutics develops therapies for neurodegenerative diseases, focusing on innovative treatments for Alzheimer's.
Cognition Therapeutics
Cognition Therapeutics (NASDAQ:CGTX) is a biopharmaceutical company focused on the discovery and development of innovative therapies for neurodegenerative diseases. Its main projects target the underlying pathophysiology of diseases such as Alzheimer's, showcasing a commitment to addressing significant unmet medical needs in the aging population. The company's objectives revolve around advancing its lead candidate, CT1812, through clinical trials, aiming to demonstrate its potential in modifying the course of Alzheimer’s disease and related conditions. By leveraging its proprietary drug discovery platform, Cognition Therapeutics is dedicated to expanding its pipeline to encompass treatments for other central nervous system disorders, aspiring to improve the lives of patients worldwide through groundbreaking science and medicine.
Resumo
Operações
Produtos e/ou serviços de Cognition Therapeutics
- Development of CT1812, a small molecule designed to protect against Alzheimer's Disease by displacing beta-amyloid oligomers from neuron receptors.
- Dry age-related macular degeneration (dry AMD): CT1812 is also being investigated for this eye disease that causes vision loss.
- Dementia with Lewy bodies: This is another form of dementia that CT1812 is being evaluated for.
- Investigation into therapies for geographic atrophy, utilizing novel mechanisms to reduce disease progression.
- Discovery and development of other product candidates: They are focused on synucleinopathies, a class of neurodegenerative diseases that includes Parkinson's disease and Multiple System Atrophy.
- Development of diagnostic tools and biomarkers for early detection of cognitive impairments and monitoring disease progression.
equipe executiva do Cognition Therapeutics
- Lisa RicciardiCEO, President & Director
- John Brendan DoyleChief Financial Officer
- Anthony O. CaggianoChief Medical Officer
- Steven A. WeissmanVP & Head of CMC
- Anita CornetHead of Quality
- Bobby HornCorporate Controller
Últimas notícias sobre a Cognition Therapeutics
Cognition Therapeutics gains FDA alignment for phase 3 DLB psychosis trial
United StatesCognition Therapeutics aligns with FDA on registrational path for lewy body dementia treatment
United StatesCognition Therapeutics reports positive results for Zervimesine in dementia with Lewy bodies.
United States
Principais indicadores financeiros
Resultados divulgados pela Cognition Therapeutics, em USD.
- Cap. de mercado
- 71,2 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -47,8 mi | -23,5 mi | |
| 0 | -54 mi | -34 mi | |
| 0 | -50,7 mi | -25,8 mi | |
| 0 | -43,6 mi | 757 mil |